Vaxxinity, Inc. (VAXX)
| Previous close | 0.0800 |
| Open | 0.0800 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0782 - 0.0920 |
| 52-week range | 0.0450 - 3.1000 |
| Volume | |
| Avg. volume | 2,264,662 |
| Market cap | 11.411M |
| Beta (5Y monthly) | 2.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5100 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.00 |
GlobeNewswireVaxxinity Issues Shareholder Letter
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu. To Shareholders of Vaxxinity, Inc.: Earlier today, we announced that we are delisting and deregistering our shares. A few weeks from now, we will no longe
GlobeNewswireVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market (“Nasdaq”) and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Sectio
- GlobeNewswire
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
Presentation will address the Company’s clinical data in Parkinson’s diseaseCAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease at the Annual Academy of Neurology (AAN) 2024 Annual Meeting, taking place April 13-18, 2024 virtually and in Denver, Colorado. Presentation details are as follows:Oral Pr
